Market Overview

Sterne Agee Reiterates Buy Rating on MedAssets Following Tenet/Vanguard Announcement

Related MDAS
Markets Edge Lower; Morgan Stanley Earnings Top Estimates
UPDATE: Bank Of America Downgrades MedAssets

In a report published Monday, Sterne Agee analyst Greg T. Bolan reiterated a Buy rating and $24.00 price target on MedAssets (NASDAQ: MDAS).

In the report, Sterne Agee noted, “This morning, Tenet Healthcare (THC, NR, $41.85) announced its intent to acquire Vanguard Health (VHS, NR, $12.37). We believe THC is MedAssets' largest client and that this acquisition represents potential new revenues to MedAssets, especially within the GPO business. MDAS remains our top pick within the HCIT industry; reiterate Buy rating and $24 PT.”

MedAssets closed on Friday at $17.59.

Posted-In: Greg T. Bolan Sterne AgeeAnalyst Color Reiteration Analyst Ratings


Most Popular

Related Articles (MDAS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free